Post by
Stevator on Jan 19, 2021 11:14pm
Biocloud vs new variants?
Has anyone yet confirmed that Biocloud is effective in recognizing the new variant(s)? If they haven't, I suspect that all the delays (the Global news piece from September reported that KNR was expecting to "roll out units worldwide starting in November") deal more with R&D than cementing sales deals. I sure hope I'm wrong, but the complete lack of sales announcements coupled with the delays and vague optimism leaves me perplexed. What's all the mystery? Better yet, why all the mystery? It certainly isn't attracting any attention for Kontrol, is it?
Comment by
GreenBull on Jan 20, 2021 2:57am
Even if we verify the new Variants, next week there will be more variants and so on. Its never ending. I am pretty confident BioCloud will detect these, it's still Sars-Cov2. I do agree Paul needs to start talking, too much mystery/uncertainty driving investors away.
Comment by
pointer on Jan 20, 2021 8:32am
This post has been removed in accordance with Community Policy
Comment by
Jilly17 on Jan 20, 2021 8:40am
I do wish that the government wakes up! Biocloud Premier Ford! https://globalnews.ca/news/7585099/coronavirus-mutations-cases-experts-worried/amp/